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Abstract 
Animal metabolic and immune systems integrate and inter-regulate to exert effective 
immune responses to distinct pathogens. The signaling pathway mediated by mechanistic target 
of rapamycin (mTOR) is critical in cellular metabolism and implicated in host antiviral 
responses. Recent studies highlight the significance of the mTOR signaling pathway in the 
interferon (IFN) response. Type I IFNs mediate host defense, particularly, against viral 
infections, and have myriad roles in antiviral innate and adaptive immunity. In addition to their 
well-known antiviral properties, type I IFNs also affect host metabolism. However, little is 
known about how animal type I IFN signaling coordinates immunometabolic reactions during 
antiviral defense. Therefore, understanding the interaction of mTOR signaling and the type I IFN 
system becomes increasingly important in potentiating antiviral immunity. 
Tissue macrophages (MФs) are a primary IFN producer during viral infection, and their 
polarization to different activation statuses is critical for regulation of immune and metabolic 
homeostasis. Using porcine reproductive and respiratory syndrome virus (PRRSV) as a model, 
we found that genes in the mTOR signaling pathway were regulated differently in PRRSV-
infected porcine alveolar MФs at different activation statuses. Therefore we hypothesize that:  1) 
the mTOR signaling pathway involves host anti-PRRSV regulation; 2) mTOR signaling interacts 
with IFN signaling to modulate the antiviral response; and 3) different type I IFN subtypes (such 
as IFN-α1 and IFN-β) regulate mTOR signaling differently. We show that modulation of mTOR 
signaling regulated PRRSV infection in MARC-145 cells and porcine primary cells, in part, 
through regulating production and signaling of type I IFNs. In addition, expression and 
phosphorylation of two key components in the mTOR signaling pathway, AKT and p70 S6 
kinase, were regulated by type I IFNs and PRRSV infection. 
  
 Taken together, we determined that the mTOR signaling pathway, a key pathway in 
regulation of cell metabolism, also mediates the type I IFN response, a key immune response in 
PRRSV infection. Our findings reveal that the mTOR signaling pathway potentially has a bi-
directional loop with the type I IFN system and implies that some components in the mTOR 
signaling pathway can serve as targets for augmentation of antiviral immunity and therapeutic 
designs. 
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Chapter 1 - General introduction 
In animals, the innate immune system acts as the first line in restriction of viral invasion 
or replication, and launches early antiviral response [1].  At the beginning of cell sensing viral 
infection, cell-associated receptors recognize viral components such as single-stranded RNA 
(ssRNA), double-stranded RNA (dsRNA), and viral genomic DNA and proteins to mount 
immune responses [2-5]. Through a cascade of signaling transduction, viral infected cells or 
activated cells are elicited to increase production of immune effectors, primarily including 
interferons (IFNs), other proinflammatory cytokines/chemokines, and antimicrobial peptides [2, 
3, 6-8]. For example, IFNs, in particular, type I IFNs as key antiviral cytokines, are induced via 
interferon regulatory factors (mainly IRF3 and IRF7), and NF-κB is responsible in modulating 
most proinflammatory cytokines and type I IFNs [6, 7, 9, 10]. Following engagement of viral 
infection and induction of these potential immune effectors, multiple cellular systems including 
both immune and metabolic systems are adapted to effectively control pathogenic invasion [1, 
11-14].  In this context, IFN signaling is the key in antiviral immune regulation, and it has also 
been discovered to have multiple roles in mediating cellular growth and proliferation rates [10, 
15-20]. Similarly, some key pathways in regulation of cell growth and metabolism, such as that 
mediated by mechanistic target of rapamycin (mTOR), have been found to be important in 
regulation of immune responses [6, 12, 13, 21]. However, currently there is a lack of platforms to 
dissect this inter-systemic interaction during viral infection. Here, type I IFN- and mTOR-
mediated pathways were used to decipher the interaction between cell immune and metabolic 
systems during viral infection. 
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 1.1 Type I IFNs 
Over the past 50 years IFNs have been discovered and used clinically in human and 
animals [15, 16]. IFNs comprise an essential family of cytokines in animal immune systems and 
have a pivotal influence on biological actions, especially those relevant to antiviral defense and 
carcinogenesis [17, 20]. 
The interferon family is divided into three classes, type I, II, and III IFNs [16]. They are 
distinguished by their distinct receptor complexes, display different expression pattern and have 
numerous functions in innate and adaptive immune responses [22]. Type I IFNs are transduced 
by their heterodimeric receptor complex (IFNAR1/2), and form the largest subgroup, comprised 
of more than 10 subtypes such as IFN-α, IFN-β, IFN-ε, IFN-κ and IFN-ω generally displayed in 
most mammalian species. Some species-specific subtypes include IFN-δ (pigs and horses), IFN-τ 
(cattle), IFN-ζ (mice) and IFN-αω (pigs, horses and cattle) [16, 23]. In addition, IFN-α, IFN-δ 
and IFN-ω are subtypes containing multiple genes. The human genome contains 13 IFN-α 
functional genes, and the swine genome contains 25, 11 and 8 functional genes of  IFN-α, IFN-δ, 
and IFN-ω, respectively [23]. IFN-γ is the only type II IFN, functioning as a homodimer and 
signaling via its receptor complex (IFNGR1/2) [24, 25]. Type III IFNs, are composed of IFN-λ1, 
IFN-λ2, IFN-λ3 (also known as IL-29, IL-28A and IL-28B, respectively) and IFN-λ4, which 
interact with distinct heterodimeric receptors of IFRL1/IL-10R2 to transmit signals [26]. Type I 
IFNs are primarily thought to be antiviral mediators, are rapidly induced upon viral infection, 
and play an indispensable role in producing rapid innate immune responses and effective 
adaptive immune responses [10]. 
Sensing pathogen associated molecular patterns (PAMPs) of viral components by cellular 
pattern recognition receptors (PRRs) is the first step to initiate and regulate type I IFN response 
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[19]. The selective features of PRRs for viral molecules and different cell types potentially 
induce differential production of specific IFN subtypes. Cytoplasmic PRRs, such as RIG-I-like 
receptors (RLRs), are specialized to recognize nucleic acids from RNA viruses. After binding to 
viral RNA, RLRs undergo a conformational change and expose their N-terminal caspase 
activation and recruitment domains (CARDs) to interact with the adaptor molecule, 
mitochondrial antiviral signaling protein (MAVS) for further generating antiviral signaling [10]. 
Membrane-bound Toll-like receptors (TLRs) also are critical to detect viral glycoproteins and 
nucleic acids and are recruited to their respective adaptors like myeloid differentiation primary 
response gene 88 (MyD88) for TLR7 and TLR9, and tumor necrosis factor receptor associated 
factor (TRIF) for TLR3 when viral nucleic acid species are recognized [10, 26]. In addition to 
PRRs, a cytosolic PAMP sensor, named cyclic GMP-AMP (cGAMP) synthase (cGAS), is 
initiated by sensing foreign DNA and activates the stimulator of IFN genes (STING) [27]. Upon 
activation of MAVS, MyD88, TRIF and STING, TRAF family is recruited to trigger mitogen 
activated protein (MAP) kinase, IKK complex and IKK-related kinases TBK1/IKKε, resulting in 
activation and nuclear translocation of AP-1, IRF3, IRF7 and NF-κB to specifically bind to 
various promoters of type I IFN genes, increasing their production [18]. 
Once type I IFNs are induced by viral infection, they are secreted by infected cells and 
stimulate target cells to start type I IFN action signaling [9, 21]. Upon type I IFNs binding to 
their specific receptors in the surface of target cells, ligand-dependent rearrangement, 
dimerization and transphosphorylation of receptors propagate downstream signaling cascades 
[28]. Receptor aggregation allows autophosphorylation and activation of associated JAKs/TYKs, 
IFNAR1 interacting with tyrosine kinase 2 (TYK2), IFNAR2 with Janus activated kinase 1 
(JAK1) [29]. Consequently phosphorylation and activation of STATs (signal transducers and 
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activators of transcription) are regulated to constitute functional homodimers or heterodimers 
which stimulate transcription of interferon-stimulated genes (ISGs) after nuclear translocation to 
bind their specific promoter sites [30]. Beyond classic JAKs/STATs signaling pathways, other 
important signaling cascades are also induced by type I IFNs for optimizing transcription of 
diverse ISGs, including MAPKKK (mitogen-activated protein kinase kinase kinase) pathway, 
PI3K (phosphoinositide 3-kinase)-AKT pathway, and mTOR (mechanistic target of rapamycin) 
signaling pathway [14, 24, 31]. Signaling cascades downstream are generated through actions of 
myriad ISGs including antiviral effectors (e.g., ISG15 and Mx1), negative regulators (e.g., 
USP18 and SOC) and positive regulators (e.g. STAT1/2 and IRF1, 3, 7, 9) [18, 21]. Following 
activation of these signaling pathways, a wide range of protective and destructive biological 
activities are evoked [32, 33]. Therefore, a balanced type I IFN response is critical to induce host 
immune responses for defense and survival (Figure 1.1). 
 1.2 mTOR signaling pathway 
 mTOR, an evolutionarily conserved serine/threonine kinase, acts as an overriding node 
for maintenance of homeostasis in animal cells [34-36]. mTOR kinase forms two functionally 
distinct multi-protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC1), to exert multiple functions through regulation of various elements downstream [36]. 
mTORC1 consists of five components: mTOR, the catalytic subunits of  the complex; 
regulatory-associated protein of mTOR (Raptor); mammalian lethal with Sec13 protein 
(mLST8); proline-riche AKT substrate 40 kDa (PRAS40); and DEP-domain-containing mTOR-
interacting protein (Deptor) [36]. Except mTOR, mLST8 and Deptor, mTORC2 includes 
rapamycin-insensitive companion of mTOR (Rictor), mammalian stress-activated protein kinase 
interacting protein (mSIN1), and protein observed with Rictor-1 (Protor-1) [36]. Genetic deletion 
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of Raptor and Rictor, fundamental subunits for mTORC1 and mTORC2 respectively, has 
provided significant insight into functions of mTORC1 and mTORC2 [37]. Over many years, 
diverse mTOR inhibitors have been developed, such as rapamycin, PP242, Everolimus, ARQ 
092 and CC214-2, and some of them including rapamycin are approved for clinical therapy [38, 
39]. The two mTOR complexes display different sensitivity to some of these inhibitors. 
Rapamycin and its analogs are the first generation mTOR inhibitors, which associate with 12 
kDa FK506-binding protein (FKBP12) to form a complex interacting with FRB (FKBP12-
rapamycin binding) domain in mTOR kinase to disrupt formation of mTORC1 [40]. Only 
mTORC1 activity is inhibited by rapamycin in a short time period, but prolonged rapamycin 
treatment also affects mTORC2 activity [41]. PP242 is a non-selective inhibitor, targets the 
adenosine triphosphate (ATP)–binding site of mTOR, and suppresses both mTORC1 and 
mTORC2 activities [42]. 
The mTOR signaling network comprised of mTORC1- and mTORC2-signaling 
pathways, senses and integrates both intracellular and extracellular signals to regulate various 
cellular processes (e.g. metabolism, growth, proliferation and survival) [36]. In recent studies, it 
has been increasingly recognized that the mTOR signaling pathway is also a vital regulator of 
innate and adaptive immune responses [12-14]. For example, Keating et al. demonstrated that the 
mTOR signaling pathway engages host antibody response to produce cross protection against 
lethal influenza infection [43]; mTORC1- and mTORC2-signaling pathways involves IFN 
production and action signaling [25, 31, 44-52]; mTOR-mediated regulation of interleukin 
production and signaling has been shown in human monocytic cells [53-55]; polarized 
macrophages (MФs) are modulated by disrupting mTOR signaling pathway [56, 57]. Thus the 
mTOR signaling pathway provides a key link between immune responses and metabolism to 
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modulate functions of immune cell populations, such as monocytes, MФs, T cells, B cells, 
dendritic cells (DCs) and neutral killer (NK) cells [13]. 
Upon stimulation of external signals such as cytokines and growth factors, the mTOR 
signaling pathway is initiated via upstream PI3K-AKT (Figure 1.1) [14, 34, 46, 51]. PI3K and 
mTORC2 activate AKT that mediates inhibitory phosphorylation of tuberous sclerosis protein 2 
(TSC2), which is associated with TSC1 to repress the phosphotransferase activity of mTOR 
through inhibiting RAS-related small GTPase RAS homologue enriched in brain (RHEB) [58, 
59]. Previous studies found that PI3K can be activated by several type I IFNs (IFN-α, IFN-β and 
IFN-ω) via inducing tyrosine phosphorylation insulin receptor substrate 1 (IRS1) or IRS2 [24, 
60, 61]. After IFNs evoking the PI3K signaling pathway downstream of JAKs, STAT1 is 
phosphorylated at Ser727 to induce STAT1-mediated gene transcription via ISREs or GAS 
(IFNγ activation site) elements [24]. In addition to JAKs/STATs signaling pathway, IFN 
signaling also is mediated by the PI3K-AKT-mTOR-ULK1-p38 mitogen-activated protein 
kinase (MAPK) pathway, revealing a critical role for the PI3K-AKT-mTOR signaling pathway 
in IFN-driven gene transcription [31, 62, 63]. 
 
 1.3 Porcine reproductive and respiratory syndrome virus 
Porcine reproductive and respiratory syndrome virus (PRRSV), the causative agent of 
most economically important swine disease that causes losses of over $800 million annually in 
United States, is a small, enveloped, single-stranded, positive-sense RNA (+ssRNA) virus [64, 
65]. It belongs to genus Arterivirus, family Arteriviridae, order Nidovirales, and was first 
identified in early 1990s in Europe (Lelystad virus, LV) and the United States (VR2332) [66, 
67]. The PRRSV genome has approximately 15kb and comprises 11 open reading frames (ORFs) 
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encoding 16 nonstructural proteins: NSP1α, NSPβ, NSP2-6, NSP2TF, NSP2N, NSP7a, NSP7b 
and NSP8-12 and  eight structural proteins: glycoprotein (GP) 2-5, GP5a, nucleocapsid (N), non-
glycosylated membrane (M) and envelope (E) proteins [68-70]. PRRSV is monocytotropic and 
primarily targets porcine alveolar MФs and monocyte-derived DCs (mDCs) to cause infection 
[71-73]. Except for MФs and mDCs, a cell line generated from kidney of African green monkey 
(MARC-145) is fully permissive to the virus and routinely used for supporting PRRSV 
replication in vitro [74]. PRRSV has evolved diverse mechanisms to evade and dysregulate 
effective host immune responses. Induction and signaling of type I IFNs, a group of critical 
antiviral cytokines, are suppressed by PRRSV infection as repeatedly observed in cells or pigs 
[69, 70, 75]. For example, PRRSV NSP1α, NSP1β, NSP2, NSP4, NSP11 and N protein regulate 
type I IFN production by adjusting phosphorylation and nuclear translocation of IRFs or/and 
activation of NF-κB signaling [68, 76-84]. Induction and processing of key antiviral ISGs, such 
as Mx1, ISG15 and ISG56, also are modulated by PRRSV infection [68]. Moreover, previous 
studies showed that: activation of PI3K-AKT signaling pathway is regulated by PRRSV 
infection in a time-dependent manner [85, 86]; PRRSV infection activates mTORC1-signaling 
and its inhibitor, rapamycin, regulates PRRSV  [87]; PI3K inhibition, AKT1 overexpression or 
mTORC1 inhibitor (rapamycin) treatment modulates viral gene transcription and protein 
synthesis [88]; PI3K-AKT signaling pathway is involved in regulation of PRRSV-mediated 
apoptosis and virus entry [89, 90]. 
 1.4 Potential interaction of mTOR and type I IFN signaling in antiviral 
regulation 
Current studies reveal that the mTOR signaling pathway displays increasing importance 
in host innate and adaptive immunity [12-14]. However, functions of the mTOR signaling 
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pathway in antiviral immunity, in particular of regulation of IFN response, remain poorly 
defined. In this study, we focus on its function in type I IFN production and signaling in antiviral 
response. 
It has been shown that both mTORC1- and mTORC2-signaling pathways are critical for 
type I IFN production and signaling [31, 49, 91]. Cao et al. report that PI3K-mTOR-p70 S6 
kinase pathway is required for TLR-induced type I IFN production in plasmacytoid DCs [50]. 
Type I IFNs coordinate mTOR signaling to selectively regulate transcription and translation of 
hundreds of ISGs [25, 44, 46, 49]. A recent study further demonstrates that ULK1 acts as a link 
between the type I IFN response and the mTOR signaling pathway and that the mTOR-ULK1 
pathway plays an indispensable role for gene transcription mediated by ISREs and GAS 
elements in type I IFN signaling [62]. In addition, the mTOR signaling pathway also can be 
activated/regulated by type I IFN response [25, 49, 51]. The function of the mTOR signaling 
pathway in anti-PRRSV innate immune response remains unknown, particularly in anti-PRRSV 
type I IFN response, albeit a few studies have shown that PI3K-AKT-mTOR signaling pathway 
involves regulation of PRRSV replication [85-90]. Furthermore, mammalian type I IFNs consists 
of multiple subtypes with different antiviral activity [15, 16]. Antiviral activities of human and 
porcine type I IFNs have been well analyzed, and porcine type I IFNs show different anti-
PRRSV activity that also is cell type-dependent [23, 92]. However, it has not been characterized 
how distinct type I IFNs regulate the mTOR signaling pathway. Therefore, PRRSV was chosen 
as a model to decipher the potential interaction of mTOR and IFN signaling in antiviral 
responses. The aims of this study were to: 1) identify functions of mTOR signaling in anti-
PRRSV regulation; 2) investigate regulation of anti-PRRSV type I IFN response by the mTOR 
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signaling pathway; and 3) explore modulation of the mTOR signaling pathway by diverse type I 
IFNs (Figure 1.1). 
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Figure 1.1 The mTOR signaling pathway interacts with the type I IFN system to regulate 
the antiviral response. 
Viral infection activates IFN signaling to produce type I IFNs and other proteins, exerting 
antiviral defense mainly via the JAKs/TYKs pathway. The mTOR signaling network, consisting 
of mTORC1- and mTORC2-signaling pathways, senses external signals primarily to modulate 
metabolism, cell growth and differentiation through the PI3K-AKT signal transduction pathway. 
AKT indirectly regulates mTORC1 activity via actions of TSC1/2. In our study, PRRSV was 
used as a model to decipher potential interaction of the mTOR signaling pathway and the type I 
IFN system in antiviral immunity. We hypothesize that 1) mTOR signaling pathway is involved 
in anti-PRRSV defense; 2) mTOR signaling interacts with type I IFN signaling to regulate 
antiviral responses; and 3) type I IFNs modulate mTOR signaling pathway differently. 
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Chapter 2 - Materials and Methods 
 2.1 Cells and viruses  
Experiments involved in animals and viruses were approved by the Kansas State 
University Institutional Animal Care and Use and Biosafety Committees. Animal procedures and 
isolation of porcine alveolar MФs and peripheral blood mononuclear cells (PBMCs) were 
previously described [93, 94]. In brief, 5-week-old clinically healthy pigs from a herd without 
viral infection history were used for collection of primary cells. PBMCs were isolated from 
blood collected by jugular venipuncture from anesthetized pigs, using Histopaque-1077 (Sigma, 
Saint Louis, MO). Immediately after euthanasia, MФs were obtained by lavaging lungs with 1× 
PBS (pH7.4, Sigma), then washing cells three times with RPMI (Roswell Park Memorial 
Institute)-1640 medium (Gibco, Carlsbad, CA). Isolated primary cells were used immediately or 
cryopreserved in Recovery™ Cell Culture Freezing Medium (Gibco). African green monkey 
kidney (MARC-145, ATCC) cells were grown in Modified Eagle’s medium (MEM, Gibco) 
containing 8% fetal bovine serum (FBS, Gibco) and 1× Antibiotic-Antimycotic (Gibco), 293FT 
cells (Invitrogen, Carlsbad, CA) in Dulbecco's Modified Eagle Medium (DMEM, Gibco) 
supplemented with 10% fetal bovine serum (FBS, Gibco), 1× MEM Non-Essential Amino Acids 
Solution (NEAA, GIBCO). MФs and PBMCs were maintained in RPMI-1640 medium 
containing 10% FBS and 1× Antibiotic-Antimycotic. mDCs were generated from PBMCs 
stimulated with IL-4 (2ng/ml) and GM-CSF (5ng/ml) (R&D Systems, Minneapolis, MN) and 
maintained in RPIM-1640 medium containing 10% FBS and 1× Antibiotic-Antimycotic [95]. 
P129-GFP and DsRed-labelled PRRSV were used in this study [93, 94, 96]. 
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 2.2 Cell polarization, viral infection and transcriptomic shotgun sequencing 
MФs have long been considered as one of most important immune effector and regulator 
cells, are distributed widely throughout the body, display multiple roles in both innate and 
adaptive immune responses, and also serve an indispensable role in inflammation and its 
resolution [97-99]. To maintain its various functions, MФs undergo phenotypical polarization in 
response to diverse environmental stimulants [100]. Typical activation statues characterized in 
MФ polarization include classical (M1) and alternative (M2) states [93, 94, 100, 101]. M1 status 
is induced in response to IFN-γ and bacterial products, such as lipopolysaccharides (LPS) [93]. 
M2 status is further categorized into three subclasses: M2a, induced by type II cytokines IL-4 or 
IL-13; M2b, obtained by triggering Fcγ receptors plus a TLR stimulus; and M2c, activated by 
glucocorticoid (GC), IL-10 and/or TGF-β [93]. 
Procedures of MФ polarization were performed as previously described [93, 94]. Briefly, 
porcine alveolar MФs were stimulated with LPS, IFN-α1, IFN-γ, IL-4 and IL-10 at 20 ng/ml for 
30 h (R&D Systems), followed by infection of P129-GFP at a multiplicity of infection (MOI) of 
0.1 for 5 h. After polarization and infection, cells were washed twice with fresh culture medium, 
and then total RNA was extracted from 3×107 cells of each treatment using a RNA/DNA/protein 
purification kit (Norgen Biotek, Ontario, Canada). To qualify for constructing RNA-Seq 
libraries, RNA concentration and quality were evaluated with a Nano-Drop 8000 spectrometer 
(NanoDrop, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA) to insure RNA samples with A260/A280>1.8 and RNA integrity number (RIN)>7.0. All 
transcriptomic shotgun sequencing was conducted following the procedures of Illumina Pipeline 
(BGI Americas, Cambridge, MA). Genome-wide transcriptomic analysis was performed using 
25-30 M clean reads per sample.  Data analyses were conducted as described [93, 94]. 
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 2.3 Antiviral analysis 
MARC-145 cells were treated with mTOR inhibitors, rapamycin and PP242, or mTOR 
activator, MHY1485 at different concentration for 12, 24, 36 or 48 h (Sigma), and then infected 
with DsRed-labelled PRRSV at MOI of 1.0 for 36-42 h. All images were collected using a Nikon 
fluorescent microscopy (Shinjuku, Tokyo, Japan) at a magnification of 20×, and viral infection 
was quantified with SpectraMax i3 (Molecular Devices, Sunnyvale, CA). Porcine primary cells 
were infected with DsRed-labelled PRRSV at MOI of 0.5 along with mTOR inhibitors or 
activator for 14-18 h, visualized with fluorescent microscopy and quantified using SpectraMax 
i3. All chemicals used were dissolved in dimethyl sulfoxide (DMSO, cell culture grade, Sigma).  
 2.4 Bioassays and ELISA 
MARC-145 cells were treated with mTOR inhibitors or activator for 24 h, and infected 
with DsRed-labelled PRRSV at MOI of 1.0 for another 24 h. Supernatants from each cell culture 
sample were inactivated with UV light for 1 h, and used to measure IFNs with a bioassay in 
MARC-145 cells stably transformed with IRF3-, IRF7- or Mx1-promoter driven luciferase 
reporter system, or an ELISA kit (R&D system) for detecting IFN-α subtypes [102]. In brief, 
MARC-145 (IRF3, IRF7, or Mx1) cells were treated with inactivated supernatants for 24 h, lysed 
with Glo lysis buffer and quantified by Steady-Glo® Luciferase Assay System (Promega, 
Madison, WI). 
 2.5 Real-Time PCR and western blotting assay 
Porcine alveolar MФs were infected by DsRed-labelled PRRSV at MOI of 0.5 along with 
mTOR inhibitors or activator treatment for 12 h, and total RNA was extracted from 2×105 cells 
of each treatment using RNA/DNA/protein purification kit. Real-Time PCR (RT-PCR) assay 
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was performed using GoTaq® 2-Step RT-PCR System (Promega). Total cDNA was reversely 
transcribed from RNA pools (2 μg RNA in a 20-μl reaction mixture) using random primers. RT-
PCR analysis was conducted using a StepOnePlus™ RT-PCR system (Applied Biosystems, 
Grand Island, NY). Reactions were run with 1 μl cDNA in a 20-μl reaction mixture, and set at 
95°C for 2 min followed by 40 amplification cycle of 95°C for 15s, 60°C for 1 min with a 
melting curve, 95°C for 15s, 60°C for 1 min, a ramp from 60°C to 95°C at an 1% rate, and 95°C 
for 15s. Critical threshold (Ct) values and melt curves were monitored and collected with 
enclosed software. Relative gene expression data were first normalized against Ct values of the 
housekeeping gene (β-Actin), and the relative expression index (2-ΔΔCt) was determined 
compared with expression levels of control sample for stimulated regulation. 
MARC-145 cells were treated with porcine IFN-α1 and IFN-β (R&D system), or infected 
with DsRed-labelled PRRSV for 24 h, then lysed using 100 μl CelLytic™ M (Sigma) for 1×106 
cells supplemented with protease inhibitors (Sigma) at 4°C for 30 min. Soluble proteins were 
collected by centrifugation at 12000× g, 4°C for 15 min. After combining with 4× LDS sample 
buffer, proteins were resolved on a 4–12% gradient Bis-Tris gel and transferred to a PVDF 
membrane using NuPAGE® electrophoresis system (NuPAGE Novex, Invitrogen). After 
blocking with 5% non-fat dry milk (Bio-Rad, Hercules, CA), filters were probed with primary 
antibodies against AKT, Phospho-AKT (Ser473), p70 S6 kinase, Phospho-p70 S6 kinase 
(Thr389) or β-Actin at 1:1000 dilution, followed by blotting with a 1:2000 fold dilution of HRP-
linked secondary antibody (Cell Signaling Technology, Danvers, MA). Blotted filters were 
imaged with a Kodak Image Station 4000 (Rochester, NY). 
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 2.6 Gene Silencing based on CRISPR/Cas9 system 
The clustered regularly interspaced short palindromic repeat (CRISPR), a short and 
repetitive segment of prokaryotic DNA, was first identified in microbially adaptive immune 
system to confer resistance to foreign viruses/phages and plasmids [103]. The CRISPR/Cas9 
(CRISPR-associated nuclease 9) system has been widely utilized for sequence-specific 
regulation of gene expression [104]. Over the past several years, this RNA-guided genomic 
editing technique has been developed extensively, involved in transcription repression and 
activation, specific sequence replacement or insertion, and gene mutation or knockout [105, 
106]. The target genes in mammalian cells can be quickly, easily and efficiently down-regulated 
by using Cas9 with one or few single guide RNAs (sgRNAs) [107]. In this study, we established 
a stably Cas9-expressing MARC-145 cell line and down-regulated Rictor and Raptor expression 
by combining 3 or 5 sgRNAs, using a lentivirus-based platform [107-109]. 
pHR-Cas9-2A-puro and phU6/BB-GFP plasmids were constructed on the basis of pHR-
SFFV-dCas9-BFP (Addgene, #46910), pSpCas9(BB)-2A-GFP (Addgene, #48138) and pgRNA-
humanized (Addgene, #44248) [107-109]. The fragment of Cas9-2A was amplified from 
pSpCas9(BB)-2A-GFP and inserted into pHR-SFFV-dCas9-BFP using MluI and BamHI, 
followed by puromycin fragment amplified from pgRNA-humanized with BamHI and SbfI. 
phU6/BB-GFP was achieved by replacing murine U6 promoter in pgRNA-humanized with 
human U6 promoter from pSpCas9(BB)-2A-GFP using XbaI and NotI, and all BbsI sites were 
mutated in pgRNA-humanized vector backbone. All sgRNA expression constructs were obtained 
with BbsI by inserting an annealed oligo pair encoding 20-nt guide sequences [107]. All 
restrictive enzymes, Quick Ligation™ Kit, Quick-Load® Taq 2× Master Mix and Phusion® 
High-Fidelity PCR Kit were purchased from New England Biolabs (Ipswich, MA). 
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Lentiviral constructs for efficient transfection and expression of Cas9 and sgRNA in 
mammalian cells were produced using a 2nd generation lentiviral system with pMD2.G 
(Addgene, #12259) and psPAX2 (Addgene, #12260). 293FT cells were transfected with envelop 
plasmid (pMD2.G), packaging plasmid (psPAX2) and transfer plasmid (pHR-Cas9-2A-puro or 
phU6/BB-xx-GFP) at a ratio of 0.9:1.5:2.1 or 0.9:1.5:1.5 (μg). Briefly, 293FT cells were grown 
in a 24 well plate overnight to reach 70% confluence and transfected with totally 1 μg DNA 
using XtremeGene9 transfection reagent (Roche, Indianapolis, IN) at a transfection reagent:DNA 
ratio of 2.5:1. After incubation for 8 h, growth medium was refreshed, and lentivirus-containing 
supernatants were collected for transducing target cells at 48 h post-transfection. The MARC-
145 cell line that stably expresses Cas9-2A-puro was established by lentiviral transduction, and 
selected with a complete culture medium including 7 μg/ml puromycin (InvivoGen, San Diego, 
CA). The pure cell line was acquired by serial dilution. After attaining MARC-145-Cas9 cells, 
they were transduced with sgRNA expressing lentiviruses to down-regulate target genes. 
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 2.7 Tables 
Table 2.1 RT-PCR primer sequences for porcine type I IFNs and their receptors [102]. 
 
Primer name Sequence (5’ to 3’) 
Product size 
(bp) 
IFN-α1 
Sense 
Antisense 
GGC TCT GGT GCA TGA GAT GT 
GCC TTC TTC CTG AAT CTG TCT TA 
337 
IFN-α5/6 
Sense 
Antisense 
GCA CAA ATG AGG AGA ATA TCT 
CCT CCT GAG TCT GTC TTG 
437 
IFN-α7/11 
Sense 
Antisense 
GGG ACT TTG GAT CCC CTC AT 
GTG GAG GAA GAG AAG GAT G 
369 
IFN-α9 
Sense 
Antisense 
GTG CTG CTC AGC TGC AAG 
AGT CCT CCT CCA GCA GGG GC 
384 
IFN-α12 
Sense 
Antisense 
CCT CAG CCT TCC TCA CGG T 
CTC ATG ACT TCT GCC CTG AT 
509 
IFN-αω 
Sense 
Antisense 
AGA TCT TCC GCC TCT TCA GCA CAA 
TTC TGG TTT CCA CCC TGA CAA CCT 
261 
IFN-β 
Sense 
Antisense 
ATG TCA GAA GCT CCT GGG ACA GTT 
AGG TCA TCC ATC TGC CCA TCA AGT 
246 
IFN-δ1 
Sense 
Antisense 
TAT AAG CTT CTG GCA GGA GT 
AGC CTT GAG TCA TCT TGT 
205 
18 
IFN-δ3/4/5 
Sense 
Antisense 
AGA ACT TGT CTG CTG TCC ATT 
TTT GGA GAA GAC ACC GGA 
209 
IFN-δ6/7 
Sense 
Antisense 
CAA TGG CCC ACA TCC ATT TGC T 
AGA TGT GTC ACA AGT GTG CCT 
214 
IFN-δ8/9 
Sense 
Antisense 
ATG CTC TGC TCC ACT CCT GC 
GTG CCT TGA GTC ATC TGG ATT GG 
194 
IFN-ε 
Sense 
Antisense 
TTG GTA CTG CTG GCT TCT TCC ACT 
AAC TGC CCT GAA GAG GCT GAA GAT 
255 
IFN-κ 
Sense 
Antisense 
GCA GAA TGA GCC ATT CGT TTC CCA 
TCC TCT TCC TCC TGC AAG CAT TGT 
259 
IFN-ω1 
Sense 
Antisense 
TGG TGC TTC TGC GTC AGA TG 
CTC ACC TGC ACC AAG CAG GAC 
265 
IFN-ω2 
Sense 
Antisense 
TTC GTG CTC TCT CTA CCG ATG 
CAG AGA TGG CCT GGA CCT 
225 
IFN-ω4 
Sense 
Antisense 
TCT GCA TCA GAT GAG GAG AC 
CAA ATG TCT GCT CTT CCA TCT 
278 
IFN-ω5 
Sense 
Antisense 
TCA TGC TCT CTC TAC TGA CAG C 
TGG AGC TTG TCC AGG AGG A 
300 
IFNAR1 
Sense 
Antisense 
ACC ACA GTG AAA CAT CAC CTG CCT 
TGT TGA TGA CGG GAG GAA ACA GGA 
349 
19 
IFNAR2 
Sense 
Antisense 
TCA ACG GGA ATC AGA GTC GTC AGA 
TCA GGA AAT ACC CAG GCG GAC AAT 
180 
β-Actin 
Sense 
Antisense 
TCG CCG ACA GGA TGC AGA AGG A 
AGG TGG ACA GCG AGG CCA GGA T 
129 
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Table 2.2 sgRNA primer sequences 
 
Primer name Sequence (5’ to 3’) 
sgRictor-1 
Sense 
Antisense 
CAC CGC CGA TCG CCG CCA TAT TGA 
AAA CTC AAT ATG GCG GCG ATC GGC 
sgRictor-2 
Sense 
Antisense 
CAC CGA TCT GAC CCG AGG TAA CGC G 
AAA CCG CGT TAC CTC GGG TCA GAT C 
sgRictor-3 
Sense 
Antisense 
CAC CGA CAA GAC CTC CAG TTC CAG A 
AAA CTC TGG AAC TGG AGG TCT TGT C 
sgRictor-4 
Sense 
Antisense 
CAC CGT AGC AGT GAT CCA AAA GGA 
AAA CTC CTT TTG GAT CAC TGC TAC 
sgRictor-5 
Sense 
Antisense 
CAC CGT CTT TCA GGT TTC ATC CCA G 
AAA CCT GGG ATG AAA CCT GAA AGA C 
sgRaptor-1 
Sense 
Antisense 
CAC CGG TCC TGG CCT TCA GCC CCG 
AAA CCG GGG CTG AAG GCC AGG ACC 
sgRaptor-2 
Sense 
Antisense 
CAC CGC ATT TCG GAC TCC ATC AGT G 
AAA CCA CTG ATG GAG TCC GAA ATG C 
sgRaptor-3 
Sense 
Antisense 
CAC CGG GAA ACT ACC AAG TTC AAG 
AAA CCT TGA ACT TGG TAG TTT CCC 
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Chapter 3 - Results 
 3.1 Genes in mTOR signaling pathway were differentially expressed in 
PRRSV-infected MФs at different activation statuses 
Genome-wide analysis of gene regulation was conducted in PRRSV-infected porcine 
alveolar MФs at different activation states as described [93, 94]. The differentially expressed 
genes (DEGs) involved in mTOR signaling pathway including mTOR complexes, their upstream 
regulators and downstream effectors, were extracted for further analysis (Figure 3.1A). Some of 
them displayed significantly differential expression and were selected as candidate targets to 
analyze antiviral regulation of MФs by mTOR signaling (Figures 3.1B and 3.1C). mTOR kinase, 
the pivotal component in both mTORC1 and mTORC2, was up-regulated in IFN-γ (M1) and IL-
4 (M2a) stimulations and down-regulated in LPS (M1) and IL-10 (M2c) treatments; however, 
mTOR kinase was less regulated by antiviral IFN-α1, indicating that mTOR is more relative to 
MФ activation status, or antiviral regulation through cell polarization [110]. Two downstream 
effectors of mTORC1 and mTORC2, RPS6KB2 (also called p70 S6 kinase) and AKT3, were 
differentially regulated by MФ polarization. The key subunit of mTORC2, Rictor, was greatly 
up-regulated by IFN-α1 [47, 111]. ULK1, acting as a crosslink for IFN-mTOR, was down-
regulated by IFN-γ, LPS and IFN-α1, and up-regulated by IL-4 and IL-10 [62]. Genes related to 
the mTOR pathway included a large group of DEGs in PRRSV-infection MФs at different 
activation statuses, which suggests that the mTOR signaling pathway is closely involved in anti-
PRRSV regulation. 
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 3.2 Regulation of PRRSV infection by the mTOR signaling pathway 
The involvement of mTOR signaling in regulation of anti-PRRSV response was first 
investigated using a pharmaceutical approach. Two mTOR inhibitors, rapamycin and PP242, and 
an mTOR activator, MHY1485, were selected to modulate the mTOR signaling pathway [42, 
112, 113]. Compared with rapamycin, which shows selective suppression primarily on 
mTORC1, PP242 is a non-selective inhibitor acting on both mTORC1- and mTORC2-signaling 
pathways. PRRSV infection was substantially repressed by mTOR inhibitors; especially, the 
non-selective inhibitor, PP242, which showed a much better effect than rapamycin in MARC-
145 cells (Figures. 3.2A, 3.2B and 3.3A). Cells treated by both rapamycin and PP242 resulted in 
an additive effect on viral repression. In contrast, the activator, MHY1485 reversed the inhibition 
of mTOR activity by PP242. The addition of MHY1485 at physiological doses to PRRSV-
infected cells, which were pre-treated with PP242, displayed a reverse effect on PP242-
suppression of PRRSV replication (Figures 3.2C and 3.3B) [114]. However, MHY1485 at a high 
concentration of 8 M inhibited PRRSV infection moderately, which could be relevant to its 
inhibitory effect on cell autophagy (Figures 3.2B and 3.3A) [113, 115]. All three tested inhibitors 
and the activator affect viral infection in a dose- and time-dependent manner (Figure 3.3A). In 
particular, prolonging rapamycin treatment significantly reduced PRRSV infection in MARC-
145 cells. Although primarily targeting mTORC1, it was shown that long-term exposure of cells 
to rapamycin also led to suppression of mTORC2 activity [116]. 
In addition, we used porcine primary cells to confirm the results from MARC-145 cells, 
an African kidney cell line frequently used for culture of PRRSV in vitro. PP242 displayed an 
inhibitory effect on PRRSV infection in both MФs and mDCs with dose-dependence as shown in 
MARC-145 cells (Figures 3.4A and 3.4B). Rapamycin showed inhibition on PRRSV infection 
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only in mDCs. The activator, MHY1485, conferred undetected effect on PRRSV infection in 
both MФs and mDCs. No cytotoxic effect was shown in MARC-145 cells and porcine primary 
cells treated with mTOR inhibitors or activator. Results suggest that inhibition of mTOR 
signaling provides a potential route to regulate anti-PRRSV response and host antiviral immunity 
is significantly modulated by mTOR signaling pathway. 
 3.3 mTOR signaling modulates the type I IFN response 
IFNs serve as critical mediators in regulation of overall antiviral response. Through 
interaction with their specific receptors, type I IFNs induce expression of a myriad of ISGs to 
exert antiviral and other biological functions [1, 18, 19]. It is implied that mTOR activity is 
closely related to type I IFN production and signal augmentation, but its involvement in PRRSV 
infection has not been studied [14, 31, 45-47, 49, 91, 117]. To test if mTOR signaling is involved 
in IFN production upon PRRSV infection, we family-wide analyzed porcine type I IFN gene 
expression in virus-infected porcine cells with pharmaceutical modulation of mTOR signaling. 
Porcine alveolar MФs were infected with PRRSV along with mTOR inhibitors or activator, and 
the expression of type I IFNs and their receptors was examined using validated primers [102]. 
We observed that PRRSV infection repressed expression of most type I IFN subtypes, including 
IFN-α1/α5/6/α9/12, IFN-δ1/3/4/5 and IFN-ω1/2/5, which are effective anti-PRRSV IFNs (Figure 
3.5A) [92, 102]. PP242 significantly reversed suppression of all analyzed type I IFN subtypes 
except for IFN-αω and IFN-β (Figure 3.5B). In comparison to PP242, rapamycin showed much 
less effect on PRRSV-induced inhibition of type I IFNs, and the activator MHY1485 only 
enhanced production of IFN-α9, IFN-δ6/7/8/9 and IFN-ω1/2 significantly. In addition, PP242 
treatment conferred high expression levels of type I IFN receptors. However, mTOR activator 
MHY1485 suppressed expression of receptor genes of IFNAR1/IFNAR2. We measured IFN-α 
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proteins secreted in culture supernatants collected from MARC-145 cells treated with mTOR 
inhibitors/activator. We showed that mTOR catalytic inhibitor PP242 was able to heighten IFN-α 
production, the most effective IFN subtype that acts against PRRSV (Figure 3.6A) [92]. 
ISGs are collection of hundreds of genes up-regulated in response to IFN production, and 
play multiple roles in antiviral regulation. Typical ISGs, including PRRs, IRFs, and other signal 
transducing proteins, work in magnifying IFN signaling or directly inactivating viruses [18]. 
IRFs, particularly IRF3 and IRF7, are critical transcription factors in mediation of both IFN 
production and action. Using the promoter-reporter system constructed with central promoter 
elements of human IRF3, IRF7 and Mx1 genes [102], we showed that PRRSV infection 
suppressed promoter activity of IRF3, IRF7 and Mx1, and the suppression was successfully 
reversed with treatment of mTOR inhibitors, rapamycin and PP242 at physiological 
concentration (Figures 3.6B, 3.6C and 3.6D). In contrast, mTOR activator, MHY1485, showed 
little effect on PRRSV-suppression on promoter activity of IRF3, IRF7 and Mx1 genes. These 
findings indicate that PRRSV replication and antiviral response in cells are significantly 
regulated through modulation of mTOR signaling, which in turn affects both cell metabolic and 
immune statuses. Furthermore, through detection of type I IFN production at mRNA and protein 
levels as well as using bio-assays to monitor ISG-stimulating activity, we showed that regulation 
of mTOR signaling in antiviral response functions, at least in part, through changing production 
or action of type I IFNs. 
 3.4 Gene silencing mTOR signaling regulates PRRSV infection 
Using a pharmaceutical approach, we have demonstrated that mTOR signaling regulates 
cell antiviral responses partly through modulation of the type I IFN system [25, 44, 45, 47, 51]. 
Here, using gene silencing, we further confirmed this observation. Raptor and Rictor are two key 
25 
subunits of mTORC1 and mTORC2, respectively. Studies showed that knockout of Raptor and 
Rictor completely blocked mTORC1- or mTORC2-pathway activity, respectively [111, 118, 
119]. Use of a newly developed genome editing system, CRISRP/Cas9, we suppressed 
transcription of either Rictor or Raptor near 60% in MARC-145 cells (Figures 3.7A and 3.7B). 
Consistent with our observation using mTOR inhibitors, genetic suppression of Rictor, the 
essential factor for mTORC2, significantly suppressed PRRSV infection in MARC-145 cells 
(Figures 3.7C and 3.7D). In contrast, PRRSV infection was only slightly inhibited by silencing 
Raptor expression. Our tests repeatedly showed that inhibition of mTORC2 activity by inhibitors 
(such as PP242 or prolonging treatment with rapamycin) or gene silencing of Rictor provided 
better protection against PRRSV infection. Bioassays of culture supernatants in stimulation of 
ISG promoter activity verified that silencing the Rictor gene enhanced the cellular capacity to 
up-regulate promoter activity of ISG genes including IRF3, IRF7, and Mx1, plausibly through 
increasing type I IFN production in Rictor-silent cells (Figures 3.7E, 3.7F and 3.7G). 
 3.5 Type I IFNs modulate mTOR signaling 
Previous studies have revealed that the mTOR signaling pathway interacts and affects 
IFN signaling transduction [25, 44, 45, 47, 51, 52, 117, 120]. For example, activation of AKT-
mTOR pathway promoted mRNA translation of IFN-stimulated genes [44]. However the 
regulation of mTOR cascade by different type I IFN subtypes and viruses has not been well 
investigated. In this study, we found that phosphorylation and expression of p70 S6 kinase and 
AKT, the key downstream effectors of mTORC1 and mTORC2 respectively, were remarkably 
regulated by porcine IFN-α1 and IFN-β, and PRRSV infection in MARC-145 cells (Figure 3.8). 
IFN-α1 and PRRSV infection stimulated phosphorylation of p70 S6 kinase at T389, which 
phosphorylates ribosomal protein S6 and translation initiation factor, eIF4B, and acts 
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downstream of mTOR signaling; however, only IFN-α1 elevated p70 S6 kinase expression [121, 
122]. In addition, IFN treatments and PRRSV infection increased expression of AKT and 
decreased its phosphorylation at S473, indicating that IFN-signaling may interact with mTOR-
signaling through regulation of AKT at different levels. In summary, type I IFNs could interact 
with the mTOR-signaling cascade at several pathway components. Modulation of the mTOR 
signaling pathway provides novel targets to regulate virus-host interaction and to potentiate 
antiviral responses. 
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Figure 3.1 RNA-Seq analysis of DEGs in PRRSV-infected porcine alveolar MФs at 
different activation statuses. 
Subsets of genes involved in mTOR signaling pathway were extracted and displayed using a 
heatmap to show relative gene expression normalized as reads per kilobase of transcript per 
million reads mapped (RPKM) (A). Some DEGs, which were significantly regulated in cytokine 
treatments compared with the control, served as candidate genes for regulation of antiviral 
response, and were further emphasized using a heatmap (RPKM) (B) and a bar chart (log of fold 
changes to the control) at the bottom (C). a=p (FDR, false discovery rate)<0.001 to the control of 
PBS.  All gene symbols are from NCBI Gene database (http://www.ncbi.nlm.nih.gov/gene/). 
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Figure 3.2 Regulation of PRRSV infection by mTOR inhibitors and activator in MARC-
145 cells. 
Cells were treated with 1 µM rapamycin, 2 µM PP242 or 2 μM MHY1485 for 24 h, then infected 
with DsRed-labelled PRRSV (MOI of 1), visualized and imaged with fluorescent microscopy 
(A) at 36 h post infection (hpi); or treated with serial dilution of mTOR inhibitors, rapamycin 
and PP242, and activator MHY1485, and quantified using SpectraMax i3 at 36 hpi (B); or pre-
treated with 2 μM PP242 for 24h, then infected with DsRed-PRRSV along with MHY1485 or 
rapamycin at different concentration, and quantified with SpectraMax i3 at 36 hpi (C). n=3, 
a=p<0.001, b=p<0.01, c=p<0.05 to the control. Rapa: rapamycin, MHY: MHY1485. 
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Figure 3.3 mTOR inhibitors and activator regulate PRRSV infection in a dose- and time- 
dependent manner in MARC-145 cells. 
Cells were pre-treated with serial dilution of mTOR inhibitors, rapamycin and PP242, or 
activator MHY1485 for 12, 24, 36 or 48 h, then infected with DsRed-labelled PRRSV (MOI of 
1), and quantified with a SpectraMax i3 at 36 hpi (A); or pre-treated with 2 μM PP242 for 12, 24, 
36 or 48 h, then infected with DsRed-PRRSV along with MHY1485 or rapamycin at different 
concentration, and quantified with SpectraMax i3 at 36 hpi (B). Rapa: rapamycin, MHY: 
MHY1485. 
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Figure 3.4 Repression of PRRSV infection by mTOR inhibitors in porcine alveolar MФs 
and mDCs. 
Cells were incubated with DsRed-labelled PRRSV (MOI of 0.5) for 1 h, and then treated with 
mTOR inhibitors (rapamycin or PP242) or activator (MHY1485) at indicated concentrations for 
another 20 h. Infected MФs (A) and mDCs (B) were quantified using a SpectraMax i3 at 20 hpi. 
n=4, a=p<0.001, b=p<0.01, c=p<0.05 to the control. Rapa: rapamycin, MHY: MHY1485. 
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Figure 3.5 mTOR inhibitors or an mTOR activator modulate expression of type I IFNs and 
their receptors in PRRSV-infected porcine alveolar MФs. 
Cells were incubated with DsRed-labelled PRRSV (MOI of 0.5) for 1 h, and then treated with 
mTOR inhibitors (Rapamycin 1 μM, or PP242 2 μM) or activator (MHY1485 2 μM) for 12 h. 
Total RNAs were extracted to analyze expression of type I IFNs and their receptors in cells 
infected with PRRSV or not (A) and PRRSV-infected cells w/wo inhibitor or activator 
treatments (B) by specific primers using two-step RT-PCR. Control was normalized to 0, n=3, 
a=p<0.001, b=p<0.01, c=p<0.05 to the control. Rapa: rapamycin, MHY: MHY1485.   
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Figure 3.6 Disruption of mTOR signaling pathway promotes type I IFN production and 
signaling. 
MARC-145 cells were treated with mTOR inhibitors (rapamycin and PP242) and activator 
(MHY1485) for 24h, and then infected with DsRed-labelled PRRSV (MOI of 1) for another 24h. 
Cell culture supernatants were collected and PRRSV was inactivated with UV illumination. 
Supernatants were used to measure IFNs with an ELISA for detection of IFN-α subtypes (A), or 
a bioassay in MARC-145 cells stably transformed with an IRF3-, IRF7- or Mx1-promoter driven 
luciferase reporter system (B, C and D). n=3, a=p<0.001, b=p<0.01, c=p<0.05 to the control. 
  
 
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
0
250
500
IRF7-promoter activity
lu
c
if
e
ra
s
e
 a
c
ti
v
it
y
a
b
PRRSV
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
0
500
1000 Mx1-promoter activity
lu
c
if
e
ra
s
e
 a
c
ti
v
it
y c
a
c
PRRSV
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
0
1000
2000
3000
IRF3-promoter activity
lu
c
if
e
ra
s
e
 a
c
ti
v
it
y
a a
PRRSV
A B
C D
IFN-  production
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
C
on
tr
ol
R
ap
am
yc
in
P
P2
42
M
H
Y1
48
5
0
20
40
60
80
IF
N
- 
 (
n
g
/m
L
)
PRRSV
33 
 
 
 
 
A B
β-Actin
Rictor
β-Actin
Raptor
si
C
on
tr
ol
si
R
ic
to
r
0.0
0.4
0.8
1.2
Rictor
R
e
la
ti
v
e
 f
o
ld
 c
h
a
n
g
e
b
si
C
on
tr
ol
si
R
ap
to
r
0.0
0.4
0.8
1.2
Raptor
R
e
la
ti
v
e
 f
o
ld
 c
h
a
n
g
e
a
 
siRictor
siRaptor
siControl
DsRed-PRRSV sgRNA Bright fieldC Merge
34 
 
 
Figure 3.7 Blocking mTOR signaling by down-regulating Rictor or Raptor expression 
suppresses PRRSV replication in MARC-145 cells. 
The gene expression of Rictor and Raptor was down-regulated using CRISPR/Cas9 system. 
Rictor expression was down-regulated by up to 70% (A), and Raptor expression near 60% (B). 
MARC-145-sgContro/sgRictor/sgRaptor cells were infected with DsRed-labelled PRRSV (MOI 
of 1), visualized and imaged with fluorescent microscopy (C), and quantified using a 
SpectraMax i3 at 36 hpi (D); or infected with DsRed-labeled PRRSV for 24 h. Then cell culture 
supernatants were collected and PRRSV was inactivated with UV illumination. Supernatants 
were used to detect IFN production and action with a bioassay in MARC-145 cells stably 
transformed with an IRF3-, IRF7- or Mx1-promoter driven luciferase reporter system (E, F and 
G). n=3, a=p<0.001, b=p<0.01, c=p<0.05 to the control. 
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Figure 3.8 Phosphorylation and expression of AKT and p70 S6 kinase, two key components 
in mTOR signaling, are differentially regulated by IFN-α1, IFN-β and PRRSV infection. 
MARC-145 cells were treated with IFN-α1 and IFN-β, or infected with DsRed-labelled PRRSV 
(MOI of 1) for 24 h. Cell lysates were resolved in SDS-PAGE to detect target proteins with 
western blotting (A). The picture shown is a representative blot of three repeats for each protein. 
Protein expression was quantified with ImageJ (B). n=3, a=p<0.001, b=p<0.01, c=p<0.05 to the 
control. 
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Chapter 4 - Conclusions and discussion 
In mammalian cells, mTOR signaling is key in orchestrating various cellular activities 
and affects host antiviral responses [43, 44, 49, 123, 124]. Type I IFNs are a group of cytokines 
critical in mediating innate and adaptive immunity against viral infection [1, 16, 125]. Our 
findings showed that, in addition to its role in regulation of cell metabolic/immune status, the 
mTOR pathway is involved in the antiviral response through modulation of type I IFN 
expression and signal processing. 
MФs were first described by Metchnikoff and are ubiquitously presented in most, if not 
all, animal tissues, and play a central role in innate immunity and regulating adaptive immunity 
[97, 98]. Their regulatory functions are mechanistically dependent on proper polarization into 
distinct activation statuses [93, 100]. PRRSV primarily attacks alveolar MФs and mDCs in its 
natural host, pigs, establishing chronic and persistent infection [73, 126]. Sang et al. showed that 
many pathways are significantly modulated in PRRSV-infected MФs at different activation 
statuses [93, 94]. It has been shown that mTOR signaling involves regulating MФ polarization 
[13, 56]. RNA-Seq analysis indicated that a large number of genes in the mTOR pathway were 
significantly and differentially regulated, including mTOR, Rictor, Raptor, AKT3, IKBKB, 
EIF4E, RPS6KB2, EIFEBP2, ULK1 and ULK2 in PRRSV-infected MФs at different activation 
statuses (Figure 3.1). The expression of Rictor, Raptor and mTOR is directly related to formation 
of mTOR complexes. ULK1 is critically important in IFN response mediated by the mTOR 
signaling pathway [31]. RNA-Seq results reveal that the mTOR signaling pathway closely 
involves antiviral regulation in MФs. 
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Protein kinase B, i.e. AKT, is a key component in mTOR signaling. Phosphorylation of 
AKT at T308 by PI3K/PDK1 or at S473 by mTORC2 acts as a main mechanism to regulate the 
activation of mTORC1 [59, 127-130]. Reciprocally, activation of mTORC1 by phosphorylated 
AKT at T308, enhances production of S6K that serves as a feedback mechanism to repress 
mTORC2 activity [59]. IFN-α1 and IFN-β increased mTORC1 activity accompanied by p70 S6 
activation; however, they decreased mTORC2 activity through suppression of AKT 
phosphorylation at S473 (Figure 3.8). Compared with IFN-α1, IFN-β did not significantly 
stimulate expression and activation of mTORC1/p70 S6 kinase, but significantly suppressed 
mTORC2/AKT activation, which could partly link to stronger anti-PRRSV activity of IFN-α1 
[92]. Blocking mTORC1 function with rapamycin treatment for short times did not confer 
protection against PRRSV. In contrast, non-selective PP242 and prolonged rapamycin 
treatments, which inhibit mTORC1 and mTORC2 activities, rendered significant suppression on 
PRRSV infection (Figures 3.2, 3.3 and 3.4). Furthermore, gene silencing of Rictor in mTORC2, 
but not Raptor in mTORC1, showed significant suppression on PRRSV infection. Our data 
obtained from both pharmaceutical treatments and genetic manipulation indicated that signaling 
mediated by mTORC2 and not mTORC1 is associated more with cell antiviral responses, and 
suggest that suppression of mTORC2 activity may provide a selective target to regulate anti-
PRRSV immune responses. Compared with studies on mTORC1, little is known about the 
biological functions mediated by mTORC2. Results here imply a potential immune regulation 
role of mTORC2 rather than the primary metabolic regulation mediated by mTORC1 [36]. 
Clearly, further studies are required to understand signaling cascades and molecular mechanisms 
of mTORC2 in regulation of antiviral immunity, in particular, its potency to be targeted for 
antiviral regulation in vivo. 
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The p70 S6 kinase (a product of the RPS6KB2 gene) is a key component in the 
mTORC1-signaling pathway. The biological function of this kinase is multifunctional, which 
includes regulation of mRNA processing, translation initiation and elongation, ribosome 
function, nascent protein folding, adipocyte differentiation, synaptic plasticity, and cell survival 
signaling [131, 132]. However, it has not been well studied in antiviral response. We showed 
here that PRRSV infection robustly increased phosphorylation but not expression of p70 S6 
kinase (Figure 3.8). The role of p70 S6 kinase phosphorylation in immune regulation thus 
requires further studies. 
Cell-dependence was observed throughout our studies to regulate the antiviral response 
via mTOR pathway.  In general, MARC-145 cells, is an established cell line containing cells 
more uniform and nearly 100% permissive to PRRSV; in contrast, porcine primary cells 
including MФs and mDCs comprise diverse cell subsets and only partially permissive to PRRSV 
in vitro [72, 73]. Therefore, we generally have a more significant and reproducible observation in 
MARC-145 cells than in porcine primary cells. For examples, both mTOR inhibitors rapamycin 
and PP242 showed increased suppressive effects against PRRSV infection in MARC-145 cells; 
however, the suppressive effect also was clearly demonstrated in porcine primary cells even with 
reasonably different kinetics (Figures 3.2B, 3.3A, 3.4A and 3.4B). In addition, porcine primary 
cells are also more sensitive to mTOR inhibitors and an activator, and relatively a lower dose and 
shorter time treatments are critical. Conversely, Sun et al. reported that rapamycin, also as an 
autophagy inducer, could promote PRRSV entrance during the early phase of viral infection 
[115]. However, we showed here that suppression of the mTOR signaling pathway, in particular 
that mediated by mTORC2 with PP242 and prolonging rapamycin treatments, significantly 
inhibited PRRSV infection in both MARC-145 and porcine cells, revealing that IFN-mTOR 
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interaction plays a more important role in antiviral regulation than modulation on MФ autophagy 
process. It is approachable at least for regulation of anti-PRRSV infection in vitro in both 
MARC-145 and porcine cells including MФs and mDCs. 
IFNs are critical antiviral cytokines [15, 19]. Most highly pathogenic viruses such as 
PRRSV have evolved diverse mechanisms to evade host IFN-mediated antiviral responses [19, 
68]. For example, PRRSV primarily inhibits type I IFN signaling pathway by targeting inhibition 
of events relevant to IRF3, NF-κB, NEMO, and ISGs, resulting in pathogenic and persistent 
infection [75]. Type I IFNs are the most important antiviral IFN subgroup and consist of multiple 
subtypes [15, 21]. Expression and antiviral function of porcine type I IFN subtypes have been 
well studied [23, 92, 102]. We found that PRRSV infection suppressed gene expression of many 
type I IFNs including most anti-PRRSV effective subtypes. Comparing rapamycin and 
MHY1485, the inhibitor PP242 significantly increased gene expression of most of type I IFNs 
and also strengthened IFN signaling transduction as shown by high receptor gene expression 
levels (Figure 3.5B). This suggests that the mTOR signaling pathway, especially mTORC2 
signaling, has a predominant role in transcription of genes related to type I IFN production and 
signaling. In addition, we showed that suppression of the mTOR pathway using PP242 induced 
production of IFN-α proteins, which are highly active against PRRSV and potentially provide a 
mean to counteract viral suppression on IFN production (Figure 3.6D) [92]. IRF3 and IRF7 are 
major transcription factors that bind interferon-stimulated response elements (ISRE) to mediate 
IFN induction. IRF3 is more potent in activating IFN-β genes than IFN-α genes [133, 134]. Not 
only functioning in stimulation of type I IFN production, IRF3 and IRF7 are also up-regulated by 
IFNs produced upon viral infection to form a positive regulatory loop in type I IFN signaling. 
Therefore, IRF3 and IRF7 are maker genes of ISGs indicating activation of IFN production 
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signaling. In addition to the difference in increasing type I IFN production, PP242 also showed a 
better reverse effect on IRF7 activation, compared with rapamycin, which partly explains why 
PP242 conferred better repression of PRRSV infection. In this context, interferon-induced 
dynamin-like GTPase genes Myxovirus 1 (Mx1) is a typical effector gene of ISGs to directly 
restrict viral infection, and serves as an indicator for type I IFN action signaling [135, 136]. 
Using promoter-reporter systems composed by promoters of these key ISGs, we measured the 
effect of modulation of mTOR pathways in IFN production and action. Together with direct 
analyses of type I IFN gene expression and protein secretion, our data showed that interfering 
with mTOR signaling, in particular through mTORC2, significantly potentiates type I IFN 
signaling, and even completely reverses PRRSV-suppression on type I IFN production. 
Therefore, polarization of cell statuses through modulation of mTOR pathway may provide an 
alteration to potentiate IFN response for antiviral regulation.  
In conclusion, we have characterized the interaction of mTOR- and IFN-signaling 
pathways in following aspects in PRRSV infection in cells:  
(1) Suppression of mTOR signaling using PP242, an inhibitor targeting both mTORC1 
and mTORC2, represses PRRSV infection;  
(2) Rapamycin, an inhibitor primarily targeting mTORC1, only significantly suppresses 
PRRSV infection during a prolonged treatment phase, when mTORC2 activity is also affected;  
(3) Gene silencing of Rictor (a component of mTORC2) but not Raptor (a component of 
mTORC1) strikingly inhibits PRRSV infection; 
(4) Production and signaling of type I IFNs, in particular of IFN-, are potentiated by 
suppression of mTOR signaling, which contributes to restriction of PRRSV infection and 
counteracts PRRSV-suppression of IFN production; 
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(5) Compared with mTORC1, mTORC2 signaling plays a more predominant role in the 
regulation of anti-PRRSV response; 
(6) The mTOR signaling pathway affects type I IFN signaling and type I IFNs also 
regulate expression and phosphorylation of key components in the mTOR signaling pathway, 
including AKT, and P70 S6 kinase, in a subtype-dependent manner.      
Taken together, these studies establish platform to investigate inter-systemic interaction 
between two key pathways of immune and metabolic systems. Further validation of these results 
in animals may lead to identification of potential targets for antiviral potentiation through 
coordinative regulation of cell growth and activation statuses. 
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